Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Habib AA, Zhao C, Aban I, França MC Jr, José JG, Zu Hörste GM, Klimiec-Moskal E, Pulley MT, Tavolini D, Krumova P, Lennon-Chrimes S, Smith J, Thanei GA, Blondeau K, Vodopivec I, Wolfe GI, Murai H.
Habib AA, et al. Among authors: zhao c.
Lancet Neurol. 2025 Feb;24(2):117-127. doi: 10.1016/S1474-4422(24)00514-3.
Lancet Neurol. 2025.
PMID: 39862880
Clinical Trial.